mRNA cos up after Sanofi snaps up Translate Bio in $3.2 bln deal

Telesis Bio

03/08/2021 13:47

(Updates)
    ** Shares of drug developer Translate Bio  TBIO.O  surge
~29.4% to $37.72 premarket 
    ** French drugmaker Sanofi SA  SASY.PA  to buy TBIO in a
$3.2 billion deal  urn:newsml:reuters.com:*:nL1N2PA0BI
    ** Sanofi, TBIO partnered last year to develop an mRNA-based
COVID-19 vaccine and they expect interim results of an
early-stage clinical trial in Q3
    ** The companies, in June last year, expanded their
partnership to develop a wide range of mRNA vaccines for
infectious diseases  urn:newsml:reuters.com:*:nL8N2E01F5
    ** Shares of CureVac  CVAC.O  which is also developing mRNA
based vaccines, including for COVID-19 up 5.7% at $52.75
premarket
     ** Shares of other mRNA vaccine and therapy developers
Arcturus Therapeutics  ARCT.O  and BioNTech SE  BNTX.O  up
between 0.3% and 7.1% premarket
    ** YTD, TBIO up ~58%, ARCT and CVAC down between 20% and
39%, while BNTX had increased more than four-fold in value up to
the last close

 (Reporting by Manojna Maddipatla and Amruta Khandekar in
Bengaluru)
 ((manojna.kalyani@thomsonreuters.com; within the U.S. +1 646
223 8780, outside the U.S. +91  80 6749 1692))